ARWR News 13.52 04/22/2014 17:21:04 Arrowhead Research Corp

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arrowhead Research Corp (ARWR) 13.52 $ARWR

35.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 16, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 3 weeks, Arrowhead Research has returned 35.34% as of today's recent price of $11.99.

Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Apr 16, 8:47AM CDT
Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate

Nasdaq stocks posting largest percentage decreases
AP - Tue Apr 15, 12:55PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:

SmarTrend Watching for Potential Rebound in Shares of Arrowhead Research After 4.87% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:45PM CDT
Arrowhead Research (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $12.32 to a high of $13.76. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $12.84 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Why Arrowhead Research (ARWR) Stock is Down Today
at The Street - Mon Apr 14, 2:00PM CDT
Arrowhead Research (ARWR) dipped Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering...

Downtrend Call Working As Arrowhead Research Stock Falls 10.2% (ARWR)
Comtex SmarTrend(R) - Wed Apr 09, 9:20AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 weeks, Arrowhead Research has returned 10.17% as of today's recent price of $16.65.

A $1 Trillion Drug Market?
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 07, 5:30PM CDT
At the Barclays Global Healthcare Conference 2014 last month, Christopher Anzalone, president and CEO of Arrowhead Research   put up a slide suggesting that its hepatitis B drug would treat a $1 trillion market "even under conservative pricing...

Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Top Gainers under the Scanner -- Research on Trina Solar, JA Solar, Arrowhead Research, and King Digital Entertainment
PR Newswire - Wed Apr 02, 8:59AM CDT
The US markets saw a positive sentiment on Tuesday, April 01, 2014, with the NASDAQ Composite closing at 4,268.04, up 1.64%, the Dow Jones Industrial Average ending the session at 16,532.61, up 0.46% and the S&P 500 edging 0.70% higher to finish the trading session at 1,885.52. The session saw a positive impact from Consumer Discretionary, Information Technology and Industrials sectors along with a drag from Utilities, and Consumer Staples sectors. A number of stocks saw large movements, including Trina Solar Ltd (NYSE: TSL), JA Solar Holdings Co. Ltd (NASDAQ: JASO), Arrowhead Research Corp. (NASDAQ: ARWR) and King Digital Entertainment PLC (NYSE: KING). Free technical research on TSL, JASO, ARWR and KING can be downloaded upon signing up at:

Why Arrowhead Research Corp. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 01, 12:36PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Arrowhead Research , a clinical-stage...

Why Arrowhead Research (ARWR) Stock Is Up Today
at The Street - Tue Apr 01, 10:24AM CDT
Arrowhead Research (ARWR) is up 12% to $18.41 in trading Tuesday

Arrowhead Completes Enrollment of First Cohort in Phase 2a Trial of Chronic Hepatitis B Candidate ARC-520
Business Wire - Tue Apr 01, 6:30AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The trial remains on schedule to meet the previously stated goal of completing dosing in the second quarter and releasing top line results in the third quarter.

3 Biotechs Falling Like a Knife: Arrowhead, Celldex, Receptos
George Budwell, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
By all accounts, biotech has had a rough week. The iShares Nasdaq Biotechnology Index is down more than 8%, and concerns over a bubble abound. Yet some companies are falling much faster than the broader sector. Are these companies becoming value...

Why Netflix, Arrowhead Research, and Trina Solar Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 24, 7:30PM CDT
The stock market finished lower on Monday, with initial enthusiasm giving way to concerns about valuations in the five-year-old bull market. Yet although most broad-based indexes escaped with only minimal losses, Netflix , Arrowhead Research ,...

Arrowhead Begins Dosing in Phase 2a Trial of RNAi Therapeutic ARC-520 in Chronic Hepatitis B Patients
Business Wire - Mon Mar 24, 6:30AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that patient dosing has begun in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The study is planned to enroll up to 16 chronic HBV patients in two dose cohorts with patients receiving either ARC-520 or placebo in combination with entecavir. The study is designed to evaluate the depth and duration of hepatitis B surface antigen (HBsAg) decline, among other measures, in response to a single dose of ARC-520. The Company anticipates planned enrollment to be complete in the second quarter of 2014 and expects top line results to be released in the third quarter.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 34

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 112

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
ACP's 1-for-4 Split Raises Price, Not Investor Value Yet

Updated Category News Views 84

Four ACP shares are about to become one, and the calculator crowd is liable to make a mountain out of a bookkeeping move. abrdn Income Credit Strategies Fund will execute a 1-for-4 reverse split before the opening bell on December 7, 2026. The quoted share price should rise by roughly four times, but the economic stake held by an investor does not magically get bigger...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
BON’s Oat Lab Bet Puts Scale and Standards in Focus

Updated Category News Views 32

Oats Meet the Industrialization Problem Oats rarely make a small-cap story more interesting, yet this one has a real business nerve running through it. Bon Natural Life has teamed with China Oat Group to establish a joint laboratory aimed at biomanufacturing high-value, oat-derived natural ingredients. The headline is not simply another research collaboration. The stated...

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Cleveland Picks Golden Key for Citywide Leadership Training

Updated Category News Views 268

A Citywide Bet on Better Management Municipal management rarely grabs headlines until something breaks, which is precisely why Cleveland's decision to bring in Golden Key Group deserves a closer look. Announced November 20, 2026, the arrangement calls for GKG to design and deliver a citywide management training program through Cleveland's Department of Personnel and Human...

Continue Reading

Top 5 Most Recently Viewed Articles

Future of Crypto: Brian Armstrong on Innovative Payment Solutions

Updated Category News Views 292

Coinbase's Vision for Payments in the Crypto World Brian Armstrong, the CEO of Coinbase Global Inc. (NASDAQ: COIN), is optimistic about the role of payments as a transformative use case within the cryptocurrency landscape. In a recent discussion, he articulated how he believes this sector will significantly evolve, particularly in terms of integrating stablecoins into...

Continue Reading
Veeva Basics Empowering Biotechs to Enhance Efficiency and Growth

Updated Category News Views 185

Veeva Basics Revolutionizes Biotech Operations In today's fast-paced biotech landscape, efficient operations are crucial. Veeva Systems (NYSE: VEEV) has introduced Veeva Basics, a solution now adopted by over 100 emerging biotechs. With this innovative approach, these companies can simplify and standardize their operations, allowing them to focus on what truly matters:...

Continue Reading
Exploring the Rise of Small-Cap Stocks: A 2024 Overview

Updated Category News Views 613

Small-Cap Stocks Lead 2024 Gains In the vibrant market of 2024, small-cap stocks have shined brighter than ever, showcasing remarkable performance that has left traditional blue-chip stocks in their wake. While larger, well-known companies often dominate discussions, smaller firms are making headlines with exhilarating returns. Remarkable Returns in the Market This year,...

Continue Reading
Ridge Street Capital Signs Significant Growth in Lending Sector

Updated Category News Views 206

Ridge Street Capital's Impressive Growth in Investment Lending Ridge Street Capital, a dynamic private lending firm, is celebrating a remarkable achievement in its operation, reporting over 150% growth from one year to the next. This impressive advancement marks the firm as a key player in investment property financing, primarily due to its tailored approach and...

Continue Reading
Kuehn Law Advocates for Sarepta Therapeutics Shareholders

Updated Category News Views 153

Kuehn Law Advocates for Sarepta Therapeutics Shareholders Kuehn Law, PLLC, a law firm dedicated to shareholder litigation, is reaching out to investors of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) regarding pressing concerns that have surfaced about the company's internal practices. Recent investigations suggest that certain officers and directors possibly did not uphold...

Continue Reading